Drugs / TNK
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06113848 Comparator | Sep 2023 → Sep 2024 | ischemic stroke | Tianjin Huanhu Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06113848 ↗ |
| Action | Inhibit | “TNK is a new generation thrombolytic agent that inhibits thrombosis” NCT06113848 ↗ |
| Route | Other | “intra-arterial TNK” NCT06113848 ↗ |